Diabetic Foot Ulcer Market Report 2026

The diabetic foot ulcer market size has grown strongly in recent years. It will grow from $6.26 billion in 2025 to $6.7 billion in 2026 at a compound annual growth rate (CAGR) of 7%. The growth in the historic period can be attributed to rising diabetic population, high prevalence of chronic foot ulcers, limited early detection practices, hospital-centric wound care, high risk of amputations.

The diabetic foot ulcer market size is expected to see strong growth in the next few years. It will grow to $9.12 billion in 2030 at a compound annual growth rate (CAGR) of 8%. The growth in the forecast period can be attributed to growth in biologic wound treatments, increasing homecare adoption, technological advancements in therapy devices, rising awareness of preventive foot care, expansion of specialty wound clinics. Major trends in the forecast period include increasing adoption of advanced wound care dressings, growing use of biologics in ulcer management, rising demand for home-based wound care solutions, expansion of therapy device utilization, increased focus on early ulcer detection.

The growing geriatric population is expected to drive the growth of the diabetic foot ulcer market in the coming years. The geriatric population includes elderly individuals, generally aged 65 years and above. Diabetic foot ulcers are a prevalent and serious issue among older adults, as seniors with diabetes are more prone to developing foot ulcers due to neuropathy, poor circulation, and slower wound-healing processes. For instance, in February 2025, according to data shared by the World Health Organization, a specialized global health agency, global life expectancy at birth reached 73.3 years in 2024, and the population aged 60 and above is projected to increase from 1.1 billion in 2023 to 1.4 billion by 2030. Therefore, the expanding geriatric population is contributing to the growth of the diabetic foot ulcer market.

The increasing use of telehealth is also expected to propel the growth of the diabetic foot ulcer market going forward. Telehealth involves the delivery of healthcare services remotely through telecommunications technologies. In the context of diabetic foot ulcers, telehealth is used to monitor wound progression and provide follow-up care without the need for frequent in-person visits. For instance, in November 2025, according to the Australian Bureau of Statistics (ABS), an Australia-based government statistical agency, 22.5% of Australians utilized telehealth services in 2024-25. Among those who participated in telehealth consultations, 90.3% indicated they would use telehealth again if available, up from 89.2% in 2023-24, reflecting growing acceptance and continued adoption. Therefore, the increasing adoption of telehealth is supporting the expansion of the diabetic foot ulcer market.

In August 2023, Coloplast A/S, a Denmark-based medical devices company focused on wound care, continence care, and intimate healthcare solutions, acquired Kerecis for up to USD 1.3 billion. Through this acquisition, Coloplast gained access to Kerecis’ patented fish-skin biologics platform, advanced wound-care technologies, and established clinical network, strengthening its advanced wound-care portfolio and expanding its global presence. Kerecis is an Iceland-based biotechnology company specializing in fish-skin-derived regenerative grafts for the treatment of chronic and complex wounds, including diabetic foot ulcers, using intact fish-skin technology that supports natural tissue regeneration and improved healing outcomes.

Major companies operating in the diabetic foot ulcer market are Cardinal Health Inc., Johnson And Johnson Private Limited, 3M Company, Medtronic plc, Medline Industries Inc., Coloplast A/S, B. Braun Melsungen AG, Nitto Denko Corporation, Smith and Nephew plc, Human Biosciences Inc., Derma Sciences Inc., Convatec Inc., Molnlycke Health Care AB., Integra LifeSciences Corporation, Lohmann And Rauscher International GmbH and Co. KG, Acelity L.P. Inc., Pliant Therapeutics Inc., MiMedx Group, BSN Medical GMBH, Osiris Therapeutics Inc., Advanced Medical Solutions Group plc, Organogenesis Inc., Healiance Inc., Misonix Inc., MediWound Ltd., Tissue Regenix Group Limited, Systagenix Wound Management Limited.

North America was the largest region in the diabetic foot ulcer market in 2025. The regions covered in the diabetic foot ulcer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the diabetic foot ulcer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the diabetic foot ulcer market by increasing costs of imported wound dressings, biologic products, and therapy devices. Hospitals and ambulatory care centers in North America and Europe are most affected due to reliance on imported advanced wound care products, while Asia-Pacific faces higher device procurement costs. These tariffs raise treatment expenses. However, they are also encouraging domestic production of wound care materials and improved regional supply capabilities.

The diabetic foot ulcer market research report is one of a series of new reports that provides diabetic foot ulcer market statistics, including diabetic foot ulcer industry global market size, regional shares, competitors with a diabetic foot ulcer market share, detailed diabetic foot ulcer market segments, market trends and opportunities, and any further data you may need to thrive in the diabetic foot ulcer industry. This diabetic foot ulcer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Diabetic foot ulcers are open wounds or sores that commonly form on the feet of people with diabetes. They represent a serious and often long-term complication of diabetes, mainly resulting from the disease’s impact on the circulatory and nervous systems. Diabetic foot ulcer treatment is aimed at improving blood sugar control and supporting vascular therapies to promote healing.

The main types of diabetic foot ulcer treatments include advanced wound care dressings, biologics, and therapy devices. Advanced wound care dressings are specialized medical dressings developed to support the healing of complex or chronic wounds. These ulcers include neuropathic ulcers, ischemic ulcers, and neuro-ischemic ulcers. The primary end users of these treatments are hospitals, ambulatory surgery centers, and home care settings.

The diabetic foot ulcer market consists of revenues earned by entities by providing diabetic foot ulcer services such as foot assessments, wound care, infection control, debridement, vascular assessment, nutritional support, compression therapy and blood sugar management services. The market value includes the value of related goods sold by the service provider or included within the service offering. The diabetic foot ulcer market also includes sales of topical antibiotics and ointments, offloading devices, special footwear, blood glucose monitors and insulin delivery devices. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.